

AMENDMENT

In the Claims:

Please cancel claims 1-28 and substitute the following claims:

44. (New) A recombinant nucleic acid comprising a nucleotide sequence that encodes a polypeptide at least 90% identical to the amino acid sequence of PHOR-1 (SEQ. ID. NO: 2) over its entire length and wherein any amino acid substitutions are conservative substitutions.
45. (New) The nucleic acid of claim 44 which encodes a polypeptide having the amino acid sequence of SEQ. ID. NO: 2.
46. (New) The nucleic acid of claim 44 wherein the polypeptide is encoded by the cDNA contained in plasmid p101P3A11 deposited with American Type Culture Collection (ATCC) as accession No. PTA-312.
- B 47. (New) The nucleic acid of claim 44 which further comprises control sequences to effect production of said PHOR-1 polypeptide.
48. (New) Recombinant cells modified to contain the nucleic acid of claim 47.
49. (New) A method to produce a PHOR-1 polypeptide which comprises culturing the cells of claim 48 whereby said PHOR-1 polypeptide is produced.
50. (New) The method of claim 49 which further comprises recovering said PHOR-1 polypeptide.
51. (New) A PHOR-1 polypeptide which comprises an amino acid sequence at least 90% homologous to the amino acid sequence of SEQ. ID. NO: 2 over its entire length and wherein any amino acid substitutions are conservative substitutions.

52. (New) The PHOR-1 polypeptide of claim 51 which comprises the amino acid sequence of SEQ. ID. NO: 2.

rule 126 ⁵³ 52. (New) The PHOR-1 polypeptide of claim 51 which is encoded by the cDNA contained in the plasmid designated p101P3A11 deposited with American Type Culture Collection as accession No. PTA-312.

54. (New) Antibodies or fragments thereof that specifically bind the PHOR-1 polypeptide of claim 44.

55. (New) The antibodies or fragments of claim 54 which are monoclonal antibodies or fragments thereof.

56. (New) The antibodies or fragments of claim 54 labeled with a detectable marker.

57. (New) The antibodies or fragments of claim 54 coupled to a toxin or therapeutic agent.

58. (New) A method to detect or determine the concentration of a PHOR-1 polypeptide which method comprises contacting a sample to be tested for the presence or concentration of said PHOR-1 polypeptide with the antibodies of claim 54 under conditions whereby a complex is formed between any PHOR-1 present in the sample and said antibodies; and

detecting the presence, amount or absence of said complex.